My Ultimate Sign-in System Made Me Invincible

The progress on the first set of volunteers continued over the coming days, and as it did, the world watching could not look away.

Diego’s legs had regenerated to his ankles by the fourth day. And the livestream carried it to the six billion people who had made the stream part of their daily rhythm — checking in the morning, watching through the afternoon, falling asleep with it running and waking to find it still there.

The comment section had developed its own culture over the days. Regulars who had been there since the first injection had become familiar names in the scroll, people tagging each other when something significant appeared on screen, building a shared vocabulary for an event that had no precedent.

Four days in, the vocabulary was still insufficient.

Maya’s progress was different from Diego’s. She was walking now, carefully, with a nurse close and her mother always within arm’s reach. It was not the full walking she would eventually manage. But walking. Her own legs, under her own weight, carrying her across the floor of a room on the moon.

Rosa watched every step without speaking.

***

The pharmaceutical sector had been bleeding for three days.

It had started as volatility but had moved past that threshold on the second day, when the tissue reconstruction on Diego’s legs became unmistakable on the livestream and the viewer count crossed 6.7B and did not come back down.

By the fourth day, it was no longer volatility but a sustained directional move, and the direction was down.

In a boardroom on the forty-seventh floor of a building in midtown Manhattan, seven people were seated around a table and the number on the screen at the far end of the room had a negative sign in front of it.

The CFO of one of the largest pharmaceutical companies in the United States had been looking at that number for forty minutes. She had looked at worse numbers before.

The number last time when Nova Technologies first announced the product was bad but not this bad.

The difference between then and now was it had been merely speculations from a far more technological advanced company. But now, the clinical trial and livestream had made it real.

And she didn’t see a way which the situation could be reversed.

The head of investor relations looked at the screen. “The trial hasn’t concluded. We don’t have final data. We don’t have regulatory filing. We don’t have approval. There’s no product on the market.”

“There are six billion people watching a twenty-two year old from Honduras regrow his legs on the moon,” the CFO said. “That is the regulatory filing.”

The room was quiet.

“The market isn’t waiting for approval,” she continued. “It’s looking at the livestream and asking a question that has nothing to do with our pipeline. It’s asking whether there is a category of human disease that nanite technology cannot address. And the honest answer — based on what we can observe from publicly available information — is that we don’t know of one.”

The head of strategic planning, who had said very little since the meeting began, looked up from the table. “Our oncology pipeline.”

“Is worth less today than it was a week ago,” she said. “Not because anything about our research has changed. Because the ceiling on what medicine can do has moved and the market is adjusting to that movement.” She paused. “This is not a normal market correction. This is the market recognizing that a foundational assumption has changed.”

Nobody argued with her.

The number on the screen had not moved in the three minutes since she had last looked at it. And if it were to move, it would be down.

***

In Washington, the reaction was being managed at several levels simultaneously.

The public position was unchanged from the statement the administration had issued weeks earlier — support for the trial, recognition of American medical professionals’ participation, the language of historic collaboration. It was the correct position and it would remain the correct position regardless of what the market was doing.

The private position was more complicated.

Patricia Yuen had been in meetings since early morning. The Treasury had questions about market stability in the healthcare sector. The FDA had questions about precedent. The Department of Commerce had questions about what a technology of this capability meant for trade relationships that had been built on assumptions the trial was systematically dismantling.

She answered what she could and held what she couldn’t and at the end of the day she sat in her office with the livestream running on a secondary screen at low volume.

On the screen, Diego was asleep.

She watched him for a while.

The number the market was producing was, she thought, actually quite honest, just an adjustment. The market was looking at what medicine had been built on and reassessing whether those foundations held.

They didn’t and anyone watching the livestream for more than an hour knew that.

The question for her office wasn’t the market. The market would find its equilibrium. The question was the infrastructure that had been built around the previous equilibrium — the regulatory frameworks, the approval pathways, the institutional relationships between government and pharmaceutical companies that had shaped health policy for decades.

That infrastructure had been designed for a world in which this was impossible.

The world had changed on a Tuesday and the infrastructure had not.

She looked at the screen. Diego’s leg was visible in the frame, the tissue now continuous from ankle to his feet, the work still running beneath the surface.

She picked up her pen and began writing.

***

In Tokyo, the Nikkei’s healthcare index had moved in a direction consistent with what the American and European markets were already doing.

In London, several major pharmaceutical companies had issued statements — careful, measured, professionally managed — acknowledging the significance of the trial while emphasizing the importance of rigorous regulatory processes.

The statements were widely read and widely understood to be the institutional equivalent of a person rearranging their expression before someone took their photograph.

In Beijing, the State Council’s internal analysis was two days ahead of anything appearing in public commentary, and the conclusions it had reached were similar to those sitting on Patricia Yuen’s desk in Washington.

The world that had been built on a particular set of assumptions about what medicine could and could not do was adjusting to a new set.

The adjustment was orderly so far. It would remain orderly, most analysts believed, for as long as the adjustment was gradual.

The livestream had been running for four days and the trial had weeks to months remaining.

Which meant that the adjustment was not going to be gradual.